Table 1.
Clinical characteristics of patients
| Population (N = 922) | |
|---|---|
| Age at diagnosis (years), median (IQR) | 52 (47, 59) |
| PNI, median (IQR) | 45.9 (40.8, 49.9) |
| SII, median (IQR) | 768.3 (486.2, 1260.1) |
| CA125 (U/mL), median (IQR) | 584.2 (168.4, 1398.0) |
| BMI (kg/m2), median (IQR) | 22.0 (20.3, 24.1) |
| Histology | |
| High-grade serous carcinoma | 597 (64.8) |
| Low-grade serous carcinoma | 28 (3.0) |
| Endometrioid carcinoma | 73 (7.9) |
| Mucinous carcinoma | 81 (8.8) |
| Ovarian clear cell carcinoma | 80 (8.7) |
| Others | 63 (6.8) |
| FIGO stage | |
| I | 191 (20.7) |
| II | 132 (14.3) |
| III | 518 (56.2) |
| IV | 81 (8.8) |
| FIGO stage | |
| I-IIA | 224 (24.3) |
| IIB-IV | 698 (75.7) |
| Tumor laterality | |
| Unilateral | 405 (43.9) |
| Bilateral | 517 (56.1) |
| Ascites | |
| No | 254 (27.5) |
| Yes | 668 (72.5) |
| Hydrothorax | |
| No | 807 (87.5) |
| Yes | 115 (12.5) |
| Menopause | |
| No | 394 (42.7) |
| Yes | 528 (57.3) |
| Comorbidities | |
| No | 775 (84.1) |
| Yes | 147 (15.9) |
| Family history of cancer | |
| No | 775 (84.1) |
| Yes | 147 (15.9) |
| Surgery methods | |
| Laparotomy | 721 (78.2) |
| Laparoscopy | 201 (21.8) |
| Lymphadenectomy | |
| No | 236 (25.6) |
| Yes | 686 (74.4) |
| Lymph node metastasis | |
| Negative | 443 (64.6) |
| Positive | 243 (35.4) |
| Residual disease | |
| R0 | 478 (51.8) |
| R1 | 272 (29.5) |
| R2 | 172 (18.7) |
| Postoperative chemotherapy | |
| No | 82 (8.9) |
| Yes | 840 (91.1) |
| Chemotherapy cycle | |
| < 6 | 394 (42.7) |
| ≥ 6 | 528 (57.3) |
| PARP inhibitors | |
| No | 912 (98.9) |
| Yes | 10 (1.1) |
| Bevacizumab | |
| No | 918 (99.6) |
| Yes | 4 (0.4) |
BMI Body mass index, FIGO International Federation of Gynecology and Obstetrics, IQR Interquartile range, PARP Poly ADP-ribose Polymerase, PFI Platinum-free interval, PNI Prognostic nutritional index, SII Systemic immune-inflammation index